An increasing body of evidence further shows that CD8+ Treg cells are able to attenuate GVHD and possess tumor-killing features (78, 79), raising the possibility of an approach consisting of the combined infusion of CD4+ and CD8+ Tregs in the future, as suggested by some authors (15, 80). Here, CD8A is linked to graft versus host disease.